E2-2, a novel immunohistochemical marker for both human and monkey plasmacytoid dendritic cells by unknown
METHODS
E2-2, a novel immunohistochemical marker for both human
and monkey plasmacytoid dendritic cells
Jianping Ma1,2, Haisheng Yu1,2, Xiangyun Yin1,2, Menglan Cheng1,2,
Quanxing Shi3, Zhao Yin3, Xiaohua Nie1, Wang Shouli3, Liguo Zhang1&
1 Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,
China
2 University of Chinese Academy of Sciences, Beijing 100080, China
3 Department of Cardiology, 306th Hospital of PLA, Beijing 100101, China
Received: 1 November 2015 / Accepted: 18 November 2015 / Published online: 11 April 2016
Abstract Plasmacytoid dendritic cells (pDCs) play important roles in initiating and regulating immune responses.
pDC inﬁltration has been documented in multiple pathological lesions including infections, tumors, and
autoimmune diseases, and the severity of pDC inﬁltration correlates with disease progression. However,
a speciﬁc antibody for identifying pDCs by immunohistochemical staining on parafﬁn-embedded tissue
sections is still lacking. Here, we developed a novel antibody targeted E2-2, a transcription factor
preferentially expressed in pDCs. The antibody stains the nuclei of pDCs speciﬁcally in immunohisto-
chemical analysis of various tissues from both human and rhesus monkey. This novel antibody will
serve as a beneﬁcial tool for pDC-related basic research and clinical investigation.
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INTRODUCTION
Plasmacytoid dendritic cells (pDCs), which are rare but
crucial component of the immunesystem, serve as a bridge
linking innate andadaptive immunity (Liu2005). pDCs can
produce 100–1000 times more type I interferon (IFN-I)
than any other cell types upon viral infections or other
stimulations (Siegal et al. 1999; Liu 2005; Reizis et al.
2011; Swiecki and Colonna 2015). In the recent years, the
involvements of pDCs inmultiple diseases, such as chronic
viral infections, autoimmune diseases, and different types
of cancers, have been extensively investigated (Tang et al.
2010; Vermi et al. 2011; Swiecki and Colonna 2015). pDC
inﬁltration in the lesion area has been reported in the
aforementioned diseases and the severity of pDC inﬁltra-
tion correlates with disease progression. In HIV/SIV
infections, for example, pDCs migrate to lymphoid organs
or mucosal tissues and contribute to pathological changes
in these areas (Nascimbeni et al. 2009; Kwa et al. 2011; Li
et al. 2013). Inﬁltration of activated pDCs to skin lesions
was also reported in psoriasis, and pDCs may promote the
morbidity through IFN-I dependent mechanism (Nestle
et al. 2005; Reizis et al. 2011). Besides, in human tumors
such as ovarian cancer, pDCs were found to be accumu-
lated in the tumor sites through upregulation of several
chemokine receptors (Zou et al. 2001; Vermi et al. 2011).
The inﬁltrated pDCs may contribute to the induction and
maintenance of immunotolerance in the tumor microen-
vironment (Vermi et al. 2011). The identiﬁcation of
immune cells by immunohistochemical analysis is essen-
tial for both clinical investigation and basic research.
However, a speciﬁc antibody for pDC staining in parafﬁn-
embedded tissue sections is still lacking.
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E2-2, which is also called transcription factor 4
(TCF4), immunoglobulin transcription factor 2(ITF2),
or SL3-3 enhancer factor 2 (SEF2), belongs to a family
of basic helix-loop-helix transcription factors named E
proteins. E2-2 is highly and preferentially expressed in
both human and murine pDCs (Cisse et al. 2008). E2-2
binds the promoters and enhancers with E-box
sequence and controls a series of genes that are critical
for pDC development and maintenance (Cisse et al.
2008; Forrest et al. 2014; Cheng et al. 2015). In this
study, we developed an anti-E2-2 monoclonal antibody,
which could speciﬁcally bind to the nucleus of pDCs on
parafﬁn-embedded tissue sections. This novel antibody
will serve as a beneﬁcial tool for pDC-related basic
research and clinical investigation.
RESULTS
E2-2 is speciﬁcally expressed in pDCs
We compared the expression of E2-2 in different
immune cells and tissues with data retrieved from
BioGPS, an online open database of cDNA array
(http://biogps.org/#goto=genereport&id=6925). E2-2
is highly expressed in pDCs, whereas its expression in
T lymphocytes (T cells), natural killer cells (NK cells),
and monocytes are at a basal level. Although B lym-
phocytes (B cells) also express E2-2, the RNA level is
much lower than that of the pDCs (Fig. 1A). In addi-
tion, there is no E2-2 expression in non-lymphoid tis-
sues, including bone marrow, heart, kidney, liver
(Fig. 1B). E2-2 mRNA level is also low in lymphoid
tissues such as tonsil and lymph nodes. This may be
due to the rarity of pDC in lymphoid tissues. We also
conﬁrmed the result with real-time PCR and found E2-
2 was highly expressed in enriched pDCs while total
peripheral blood mononuclear cells (PBMC) showed
nearly no expression (Fig. 1C). In summary, the tran-
scription factor E2-2 is highly and preferentially
expressed in pDCs and could serve as a pDC-speciﬁc
marker.
The stable secondary structure exists
in the latter half of the E2-2 protein
As E2-2 is preferentially expressed in pDCs, we chose
this molecule as the target for the pDC immunohisto-
chemical staining. For subsequent monoclonal antibody
development, it is crucial to prepare synthetic E2-2
protein/peptide with stable structure to be used as
immunogen. We analyzed amino acid sequence with the
online protein secondary structure prediction server-
Jpred 4 and the result showed only three short alpha-
helix domains existing in the latter half of the protein,
with the remaining sequence having no deﬁnite
Fig. 1 E2-2 expression proﬁle in different immune cells and
different tissues. A Comparison of E2-2 expression level in pDC
and other immune cells in human blood. B Comparison of E2-2
expression level in pDC and tissues from different human
organs. (Data from BioGPS database, http://biogps.org/#goto=
genereport&id=6925.) C The relative mRNA level of E2-2 in
pDC and total peripheral blood mononuclear cells by RT-PCR.
(Data were based on three independent experiments.) The data
are presented as mean ± SEM of results from two samples in
BioGPS cDNA array tests and three different samples in the
real-time PCR test
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structures predicted by the server (Fig. 2A). In addition,
previous study also demonstrated that there are multi-
ple alternative splicing sites in the ﬁrst half of E2-2
(Sepp et al. 2011). As a result, we selected and cloned
the latter half of the E2-2 protein (amino acid sequence
from 362 to 671) for in vitro expression (Fig. 2B). In
addition, results of amino acid sequence alignment
among several species of mammals indicate that the
selected fragment is conserved, and antibody targeted
to this fragment may cross-react with other species as
well (Fig. 3).
The novel monoclonal antibody speciﬁcally binds
E2-2
After 4 times of immunization with the puriﬁed E2-2
fragment mentioned above and screening based on
enzyme-linked immunosorbent assay (ELISA), we
selected one clone (10F7), which showed highest
binding ability during the screening, and tested its
performance in the subsequent experiments. We found
that the clone 10F7 could bind E2-2 speciﬁcally in
Western blot, as the band density increased as the
escalated dosage of E2-2 expression plasmid transfected
in the HEK293T cells (Fig. 4, lane 2–5), whereas non-
transfected HEK293T cells showed no E2-2 expression
(Fig. 4, lane 1).
The 10F7 antibody can be used to stain human
pDCs on parafﬁn-embedded tissue sections
We tested 10F7 binding of pDCs by immunohisto-
chemical staining in human tissue sections and com-
pared its speciﬁcity with the anti-CD123 antibody,
which is the most commonly used antibody for pDC
staining. As reported previously, we found that the anti-
CD123 could stain the cell surface of pDCs. In addition,
the high endothelial venules (HEV) are also positive for
CD123 staining (Fig. 5B, D). However, 10F7 clearly
stained the nuclei of pDCs which agrees with the
nuclear localization of E2-2. It is noteworthy that the
nuclear staining property of 10F7 distinguished pDCs
from other cells around them more clearly.
To conﬁrm the binding speciﬁcity of 10F7, we also
did double-staining of 10F7 with anti-CD3 antibody (T
lymphocytes) (Fig. 6A) or anti-CD20 antibody (B lym-
phocytes) (Fig. 6B). No co-localization of 10F7 with CD3
or CD20 was observed, which conﬁrmed that 10F7
staining is pDC-speciﬁc. In addition, double-staining of
10F7 with anti-CD123 antibody (Fig. 6C) also suggests
higher speciﬁcity of our novel antibody for pDC staining
in immunohistochemistry.
The 10F7 antibody binds to macaque pDCs
In consistent with the high homology between human
and monkey sequences of the selected E2-2 fragment
as immunogen, the 10F7 could cross-react with non-
human primates (Fig. 7). 10F7 antibody has a similar
nuclear staining in the axillary lymph node samples of
rhesus macaque (Fig. 7A) and the speciﬁcity is higher
compared with the anti-CD123 antibody (Fig. 7B, C). To
further conﬁrm this in other tissues, we also stained
the pDCs with 10F7 in sections of macaque spleen (SP)
(Fig. 7D), axillary lymph node (aLN) (Fig. 7E), sub-
maxillary lymph node (smLN) (Fig. 7F), and inguinal
lymph node (iLN) (Fig. 7G). In summary, 10F7 could
stain monkey pDCs speciﬁcally on the parafﬁn-
embedded tissue sections.
DISCUSSION
Although tremendous progresses have been made since
the discovery of pDCs (Reizis et al. 2011; Swiecki and
Colonna 2015), a speciﬁc marker for identifying pDCs in
parafﬁn-embedded tissue sections by immunohisto-
chemistry analysis is still lacking. CD123 has been used
as a pDC marker in the immunohistochemistry (Masten
et al. 2006; Kutzner et al. 2009; Dave et al. 2012,).
However, CD123 also expressed on high endothelial
Fig. 2 The expression of truncated E2-2 as immunogen. A The
secondary structure of E2-2 protein was analyzed with Jpred4 as
described in the method section. One region with three alpha-
helix structures (amino acid sequence from 567 to 626) was
shown. The second half (amino acid sequence from 362 to 671)
was selected as the immunogen. B The puriﬁed E2-2 polypeptide
was analyzed in SDS-PAGE gels and stained with Coomassie
Brilliant Blue. The band between 35 and 40 kDa was truncated
E2-2
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venules (HEVs) or myeloid cells (Vermi et al. 2011). To
discriminate pDCs with myeloid dendritic cells (mDCs),
Nishikawa used a combination of 2 markers, S100B and
fascin, in the immunohistochemistry analysis of human
pathological tissues (Nishikawa et al. 2009). In 2013,
Montes-Moreno et al. (2013) reported that SPIB might
be a novel immunohistochemistry marker for the diag-
nosis of blastic plasmacytoid dendritic cell neoplasms
Fig. 3 The alignment of E2-2 sequences between different species
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(BPDCN), one kind of leukemia related to pDCs
(Cronin et al. 2012). However, the speciﬁcity of this
marker is not ideal, as some proportions of the B cell
and T-cell lymphomas can also be positive for SPIB
(Boiocchi et al. 2013; Montes-Moreno et al. 2013).
Boiocchi et al. (2013) proposed that BDCA-2, which is
also preferentially expressed in pDCs, should be
included as an additional marker to SPIB for the
normal or neoplastic pDC staining. In this study, we
developed a novel monoclonal antibody, the 10F7,
which targets to E2-2, a transcription factor prefer-
entially expressed in pDCs. The immunohistochemistry
analysis showed a clear-cut staining of the nucleus of
pDCs. Although very low level E2-2 expression in B
cells has been documented (Cisse et al. 2008), our
study demonstrates no obvious staining in both B and
T lymphocytes. In addition, E2-2 is a more speciﬁc
pDC marker than the commonly used CD123 in the
immunohistochemical analysis. Since the amino acid
sequence of the truncated E2-2 is conserved among
species, 10F7 can also cross-react with pDCs from
rhesus macaques, which implied its potent use in the
non-human primate model studies. We hope this
antibody could serve as an additional tool for
immunohistochemistry analysis of pDCs in both clini-
cal and basic research. Additionally, we observed a
high homology of E2-2 sequences between different
species (Fig. 3). If 10F7 could also stain E2-2 in other
species, it will be an ideal tool to study pDC in those
animals.
MATERIALS AND METHODS
E2-2 protein structure prediction, gene cloning,
and expression
The secondary structure of E2-2 was analyzed with
online server-Jpred4, and the amino acid sequence from
362 to 671 with three predicted stable alpha-helix
domains was selected as immunogen (http://www.
compbio.dundee.ac.uk/jpred4/index.html). The coding
sequence was cloned into the pET vector with His tag on
the C termini and transformed into E. coli for the protein
production. The protein was puriﬁed with the Nickel
column and then used as immunogen.
Fig. 4 The binding speciﬁcity of 10F7 to E2-2 by Western blot. The binding of 10F7 was tested with HEK293T cells transfected with
different quantities (ng/well) of E2-2 expressing plasmid. The polyclonal antibody was used to stain the HA-tagged E2-2 protein as well.
The tubulin was used as an internal loading control
Fig. 5 10F7 stains pDCs in different human tissues. The binding
speciﬁcity of 10F7 (A, C, and E) and anti-CD123 (B, D, and
F) antibody was compared on slides with parafﬁn-embedded
human tissue, including breast cancer draining lymph node (A and
B), tonsil (C and D) and large intestine tissue form colon cancer
patient (E and F) (10F7 and anti-CD123, brown; hematine, blue)
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Animals, immunization, and antibody screening
The BALB/c mice used in this study for the monoclonal
antibody preparation were purchased from Vital River
and maintained following the national and institutional
guidelines for laboratory animals. Mice were immunized
subcutaneously once a month for four times with the
puriﬁed E2-2 fragment at a dosage of 60 lg/mouse with
15 lg CpG1826 as the adjuvant. Three days after the
last immunization, the mouse was sacriﬁced and the
spleen was obtained for single cell suspension. At last,
the splenocytes were fused with Sp2/0 myeloma cells.
The screening was carried out with ELISA.
Antibody puriﬁcation
The hybridoma was injected into Rag2-/- cc-/-
immunodeﬁciency mice and ascites was collected. Then
the antibody was puriﬁedwith the protein G Sepharose 4
Fast Flow (GE Healthcare) following the vendor’s
instruction. Brieﬂy, the ascites was diluted in the binding
buffer (20 mmol/L sodium phosphate, pH 7.0) at a ratio
of 1:5. Then the diluted ascites was added to the protein
G-Sepharose column. At last, the antibody was collected
with the elution buffer (0.1 mol/L glycine, pH 2.5–3.0)
and mixed with the neutralizing solution (1 mol/L
Tris-HCl, pH 9.0). Then the antibody was washed with
PBS (pH 7.0–7.4) and condensed in a 30-kDa Amicon
Ultra-15 Centrifugal Filter Units (Amicon).
RNA extraction, reverse transcription, and Real-
time PCR
RNAs of pDCs and PBMCs were extracted from TRIzol
reagent (Invitrogen)-treated samples. cDNA was syn-
thesized with Moloney Murine Leukemia Virus Reverse
Transcriptase (Promega). The expression level of E2-2
in different samples was tested with CYBR Green mix on
the Rotor-Gene Corbett 65HO (Corbett Life Science).
The primers used in this study are as follows:
Fig. 6 10F7 speciﬁcally stains pDCs by immunohistochemistry. The localization of 10F7-stained pDC, the anti-CD3 antibody-stained T
cells (A) and anti-CD20 antibody-stained B cells (B) in human tonsil was analyzed (10F7, brown; anti-CD3 and CD20, dark blue; hematine,
light blue). C A co-staining of 10F7 and anti-CD123 antibody in human tonsil (10F7, brown; anti-CD123, blue)
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EF-1a reverse, 50-GTGGG GTGGCAGGTATTAGG-30.
Cell sorting with ﬂow cytometry
PBMCs were stained with the following antibodies:
mouse anti-human CD3/CD14/CD16/CD19 (lineage)
Fig. 7 10F7 stains monkey pDCs in the lymph nodes. 10F7 (A) and anti-CD123 antibody (B) staining of monkey axillary lymph node.
(10F7 and anti-CD123 antibody, brown; hematine, blue). C A co-staining of 10F7 and anti-CD123 antibody in monkey sub-maxillary lymph
node (10F7, brown; anti-CD123 antibody, blue). 10F7 staining of monkey spleen (D), axillary lymph node (E), sub-maxillary lymph node
(F), and inguinal lymph node (G) (10F7, brown; hematine, blue)
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antibody conjugated with FITC, CD11c antibody conju-
gated with APC, HLA-DR antibody conjugated with APC-
Cy7, and CD123 antibody conjugated with BV421. All
the antibodies were products of BioLegend. The pDCs
were gated as lineage-HLA-DR?CD123? and sorted
with the ﬂow cytometer (FACSAria, BD Biosciences).
Immunohistochemistry
The human and monkey tissues were ﬁxed with 4%
paraformaldehyde (PFA) and embedded with parafﬁn.
For antigen retrieval, the EDTA retrieval buffer (pH 9.0)
was used. The mouse anti-human CD123 (NCL-L-
CD123, Leica Biosystems) was used for comparison in
this study. The reagents used for the staining were
Polymer HRP Detection System (PV-9002, ZSGB-BIO) for
single-staining and DouSP (KIT-9999, MXB) for double-
staining. The developing reagents were DAB (ZLI-9018,
ZSGB-BIO) and VECTOR BLUE SUBSTRATE KIT (SK-
5300, Vector Laboratories, Inc).
Immunohistochemistry images were taken by the
Nikon binocular microscope (Eclipse Ci-L, Nikon) and
imaging system (DS-Ri2, Nikon).
Western blotting
The HEK293 T cells were transfected with E2-2
expressing plasmid at different quantities. 48 h later, the
cells were harvested and lysed for the preparation of the
protein extracts. The extracts were separated with SDS-
PAGE and transferred to the polyvinylidene diﬂuoride
(PVDF) membrane. The 10F7 antibody, rabbit anti-HA
polyclonal antibody, and anti-tubulin were incubated
with the membrane overnight at 4 C. After incubation
with the secondary HRP-conjugated antibody, the
development was carried out with the HRP substrate
(Millipore).
Statistical analysis
The expression levels of the E2-2 in different cells and
tissues were analyzed by GraphPad Prism 6 software.
The data shown were means of ±SEM for the result of
two samples in BioGPS cDNA array tests and three dif-
ferent samples in our real-time PCR test. Statistically
signiﬁcant differences were determined by unpaired
Student’s t test, and P value\0.05 was considered as
statistically signiﬁcant.
Abbreviations
BPDCN Blastic plasmacytoid dendritic cell neoplasm
ELISA Enzyme-linked immunosorbent assay
HEV High endothelial venules
HIV Human immunodeﬁciency virus
IHC Immunohistochemistry
ITF2 Immunoglobulin transcription factor 2
pDC Plasmacytoid dendritic cell
SEF2 SL3-3 enhancer factor 2
SIV Simian immunodeﬁciency virus
TCF4 Transcription factor 4
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